Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Prothena Corporation plc PRTA

Healthcare Biotechnology
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the... see more

Recent & Breaking News (NDAQ:PRTA)

Prothena to Report Second Quarter 2021 Financial Results on August 5th

GlobeNewswire July 29, 2021

Prothena Presents New Data from Robust Alzheimer's Portfolio at the Alzheimer's Association International Conference 2021

GlobeNewswire July 26, 2021

Prothena to Present Data from Two of its Alzheimer's Disease Programs at the Alzheimer's Association International Conference 2021

GlobeNewswire July 20, 2021

Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena's ATTR Amyloidosis Programme

GlobeNewswire July 12, 2021

Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration

GlobeNewswire June 24, 2021

Prothena to Participate in JMP Securities Life Sciences Conference on June 16

GlobeNewswire June 10, 2021

Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors

GlobeNewswire May 20, 2021

Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update

GlobeNewswire May 11, 2021

Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson's Disease

GlobeNewswire May 10, 2021

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 7, 2021

Prothena to Report First Quarter 2021 Financial Results on May 11th

GlobeNewswire May 4, 2021

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021

GlobeNewswire April 18, 2021

Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021

GlobeNewswire April 15, 2021

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 7, 2021

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

GlobeNewswire April 5, 2021

Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares

GlobeNewswire March 24, 2021

Prothena Announces Proposed Offering of Ordinary Shares

GlobeNewswire March 23, 2021

Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021

GlobeNewswire March 8, 2021

Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021

GlobeNewswire February 24, 2021

Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update

GlobeNewswire February 11, 2021